{"denoms":[{"counts":[{"groupId":"BG000","value":"10"}],"units":"Participants"}],"groups":[{"description":"INCAGN01876 in combination with pembrolizumab and epacadostat","id":"BG000","title":"INCAGN01876 + Pembrolizumab + Epacadostat"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","spread":"13.73","value":"64.2"}]}]}],"dispersionType":"STANDARD_DEVIATION","paramType":"MEAN","title":"Age, Continuous","unitOfMeasure":"years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"3"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"7"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"1"}],"title":"Hispanic or Latino"},{"measurements":[{"groupId":"BG000","value":"9"}],"title":"Not Hispanic or Latino"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Race/Ethnicity, Customized","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"8"}],"title":"White/Caucasian"},{"measurements":[{"groupId":"BG000","value":"1"}],"title":"Asian"},{"measurements":[{"groupId":"BG000","value":"1"}],"title":"Other"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Race/Ethnicity, Customized","unitOfMeasure":"Participants"}],"populationDescription":"The Full Analysis Set (FAS) includes all subjects enrolled in the study who received at least 1 dose of INCAGN01876, pembrolizumab, or epacadostat."}